City

Houston (1)

Philadelphia (1)

Overall Status

Active, not recruiting (2)

Phase

phase 2 (2)

Sponsor

ECOG-ACRIN Cancer Research Group (1)

M.D. Anderson Cancer Center (1)

Collaborator

National Cancer Institute (NCI) (2)

Intervention

capecitabine (1)

carboplatin (1)

cisplatin (1)

dna plasmid-encoding interleukin-12/hpv dna plasmids therapeutic vaccine medi0457 (1)

durvalumab (1)

fluorouracil (1)

laboratory biomarker analysis (1)

paclitaxel (1)

quality-of-life assessment (1)

Study Documents

Intervention Type

biological (1)

drug (1)

other (1)

Funder Type

Other (2)

Study Type

Interventional (2)

recurrent anal canal carcinoma

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Squamous Cell Carcinoma Trial in Philadelphia (Capecitabine,

Active, not recruiting

Anal Basaloid Carcinoma
+6 more

Capecitabine
+6 more

Philadelphia, Pennsylvania

ECOG-ACRIN Cancer Research Group

Jan 3, 2023

Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive, Metastatic Malignant Tumor Trial in Houston (DNA

Active, not recruiting

Human Papillomavirus-16 Positive
+20 more

DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457
Durvalumab

Houston, Texas

M D Anderson Cancer Center

Feb 11, 2022